Endeavour Silver Corp vs Zimmer Biomet Holdings Inc — how do they compare? Endeavour Silver Corp trades at $8.76 (market cap $2.54B), while Zimmer Biomet Holdings Inc trades at $89.31 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 6.7× Endeavour Silver Corp's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EXK | ZBH | |
|---|---|---|
Market Cap | $2.54B | $16.95B |
Volume | 7,077,330 | 2,505,240 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $103.98 |
52-Week Low | $7.07 | $79.58 |
Typical Hold Time | 25 Days | 89 Days |
Enterprise Value | $2.54B | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.77, up 5.41% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, with revenue projected to grow from $468M in 2025 to $737M in 2026. Recent developments include operational progress at Terronera mine and resolution of blockade issues, while maintaining a 78.57% analyst buy rating.
EXK presents growth potential through mine expansions and favorable silver prices, but faces execution risks from operational disruptions and negative 2025 net income. The stock's high P/E ratio of 42.85 suggests premium valuation, requiring careful monitoring of production targets and cost management for sustained profitability improvement.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →